keyword
MENU ▼
Read by QxMD icon Read
search

Grade 2 MCL

keyword
https://www.readbyqxmd.com/read/27900638/bendamustine-plus-rituximab-for-previously-untreated-patients-with-indolent-b-cell-non-hodgkin-lymphoma-or-mantle-cell-lymphoma-a-multicenter-phase-ii-clinical-trial-in-japan
#1
Michinori Ogura, Kenichi Ishizawa, Dai Maruyama, Naokuni Uike, Kiyoshi Ando, Koji Izutsu, Yasuhito Terui, Yoshitaka Imaizumi, Kunihiro Tsukasaki, Kenshi Suzuki, Tohru Izumi, Kensuke Usuki, Tomohiro Kinoshita, Masafumi Taniwaki, Nobuhiko Uoshima, Junji Suzumiya, Mitsutoshi Kurosawa, Hirokazu Nagai, Toshiki Uchida, Noriko Fukuhara, Ilseung Choi, Ken Ohmachi, Go Yamamoto, Kensei Tobinai
A Phase II, multicenter clinical trial of bendamustine plus rituximab (BR) regimen was conducted in previously untreated patients with high-tumor-burden indolent B-cell non-Hodgkin lymphoma (B-NHL) and previously untreated elderly patients with mantle cell lymphoma (MCL) in Japan. Bendamustine 90 mg/m(2)/day on days 1 and 2, as well as rituximab 375 mg/m(2) on day 1 were administered intravenously up to six cycles. The primary endpoint was the complete response (CR) rate as assessed by the International Workshop Response Criteria (1999)...
November 29, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27644607/clinicopathologic-assessment-of-ocular-adnexal-lymphoproliferative-lesions-at-a-tertiary-eye-hospital-in-iran
#2
Fahimeh Asadi-Amoli, Zohreh Nozarian, Hirbod Nasiri Bonaki, Vahid Mehrtash, Samaneh Entezari
BACKGROUND: The most common type of ocular lymphoma is non-Hodgkin lymphoma (NHL), categorized into two groups: indolent (slow growing) and aggressive (rapid growing). Differentiating benign reactive lymphoid hyperplasia (RLH) from malignant ocular adnexal lymphoma (OAL) is challenging. Histopathology, immunohistochemistry (IHC) and ow cytometry have been used as diagnostic tools in such cases. MATERIALS AND METHODS: In this retrospective case series, from 2002 to 2013 at Farabi Eye Center, 110 patients with ocular lymphoproliferative disease were enrolled...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27616553/efficacy-and-safety-of-ibrutinib-in-japanese-patients-with-relapsed-or-refractory-mantle-cell-lymphoma
#3
Dai Maruyama, Hirokazu Nagai, Noriko Fukuhara, Toshiyuki Kitano, Takayuki Ishikawa, Hirohiko Shibayama, Ilseung Choi, Kiyohiko Hatake, Toshiki Uchida, Momoko Nishikori, Tomohiro Kinoshita, Yoshihiro Matsuno, Tomoaki Nishikawa, Satoko Takahara, Kensei Tobinai
In this multicenter, single-arm, phase II study, efficacy and safety of ibrutinib were examined in Japanese patients with relapsed or refractory mantle cell lymphoma (MCL). Patients (age ≥ 20 years) with relapsed or refractory MCL who had progressed after receiving at least one prior treatment regimen, were enrolled. Patients were treated with oral ibrutinib (560 mg/once daily; 28-day cycle) until disease progression (or relapse), unacceptable toxicity, or study end. Primary endpoint was overall response rate (ORR)...
September 12, 2016: Cancer Science
https://www.readbyqxmd.com/read/27435334/acute-mcl-and-acl-injuries-first-results-of-minimal-invasive-mcl-ligament-bracing-with-combined-acl-single-bundle-reconstruction
#4
A Ateschrang, S Döbele, T Freude, U Stöckle, S Schröter, T M Kraus
BACKGROUND: There is an on-going discussion whether to operatively treat combined grade II and III lesions of the medial collateral ligament (MCL) with anterior cruciate ligament (ACL) in the acute phase rather than conservative treatment of the MCL lesion with a delayed unitary ACL replacement. Another issue is the question how to technically address these MCL lesions. The aim of this study was, therefore, to analyze the results of simultaneous ACL replacement (hamstrings) in a single-bundle technique with a simultaneous MCL ligament bracing procedure...
September 2016: Archives of Orthopaedic and Trauma Surgery
https://www.readbyqxmd.com/read/27354719/lenalidomide-bendamustine-rituximab-in-untreated-mantle-cell-lymphoma-65-years-the-nordic-lymphoma-group-phase-i-ii-trial-nlg-mcl4
#5
Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Jan Sundberg, Lone Bredo Pedersen, Elisabeth Ralfkiær, Marja-Liisa Karjalainen-Lindsberg, Christer Sundström, Mats Ehinger, Christian Geisler, Mats Jerkeman
For elderly patients with mantle cell lymphoma (MCL), there is no defined standard therapy. In this multicenter open-label phase I/II trial we evaluated the addition of lenalidomide (LEN) to rituximab-bendamustine (R-B) as first-line treatment to elderly MCL patients. Patients >65 years with untreated MCL, stage II-IV were eligible for inclusion. Primary endpoints were maximally tolerable dose (MTD) of LEN, and progression-free survival (PFS). Patients received six cycles q4w of L-B-R (L D1-14, B 90 mg/m(2) iv D1-2 and R 375 mg/m(2) iv D1) followed by single LEN (D1-21, q4w, cycles 7-13)...
June 27, 2016: Blood
https://www.readbyqxmd.com/read/27313086/addition-of-high-dose-cytarabine-to-immunochemotherapy-before-autologous-stem-cell-transplantation-in-patients-aged-65-years-or-younger-with-mantle-cell-lymphoma-mcl-younger-a-randomised-open-label-phase-3-trial-of-the-european-mantle-cell-lymphoma-network
#6
RANDOMIZED CONTROLLED TRIAL
Olivier Hermine, Eva Hoster, Jan Walewski, André Bosly, Stephan Stilgenbauer, Catherine Thieblemont, Michal Szymczyk, Reda Bouabdallah, Michael Kneba, Michael Hallek, Gilles Salles, Pierre Feugier, Vincent Ribrag, Josef Birkmann, Roswitha Forstpointner, Corinne Haioun, Mathias Hänel, René Olivier Casasnovas, Jürgen Finke, Norma Peter, Kamal Bouabdallah, Catherine Sebban, Thomas Fischer, Ulrich Dührsen, Bernd Metzner, Georg Maschmeyer, Lothar Kanz, Christian Schmidt, Richard Delarue, Nicole Brousse, Wolfram Klapper, Elizabeth Macintyre, Marie-Hélène Delfau-Larue, Christiane Pott, Wolfgang Hiddemann, Michael Unterhalt, Martin Dreyling
BACKGROUND: Mantle cell lymphoma is characterised by a poor long-term prognosis. The European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation (ASCT) improves outcome. METHODS: This randomised, open-label, parallel-group, phase 3 trial was done in 128 haemato-oncological hospital departments or private practices in Germany, France, Belgium, and Poland...
August 6, 2016: Lancet
https://www.readbyqxmd.com/read/27281885/-efficacy-comparison-between-deep-medial-collateral-ligament-repair-and-conservative-treatment-for-complete-medial-collateral-ligament-rupture
#7
COMPARATIVE STUDY
Hangzhou Zhang, Xizhuang Bai, Qingwei Liang, Yanfeng Wang, Xiangnan Liu, Fuli You
OBJECTIVE: To compare the clinical efficacy between deep medial collateral ligament (dMCL) repair and conservative treatment for complete MCL rupture. METHODS: Between August 2009 and December 2013, 36 patients with grade 3 MCL rupture underwent superior MCL (sMCL) reconstruction with tibial Inlay technique. Of 36 cases, 19 received dMCL repair (repair group), and 17 received conservative treatment (conservation group) after sMCL reconstruction. There was no significant difference in gender, age, knee sides, type of injury, disease duration and preoperative medial joint opening, knee Lysholm scores, and International Knee Documentation Committee (IKDC) score between 2 groups (P > 0...
March 2016: Chinese Journal of Reparative and Reconstructive Surgery
https://www.readbyqxmd.com/read/27172899/metabolic-reprogramming-of-glioblastoma-cells-by-l-asparaginase-sensitizes-for-apoptosis-in-vitro-and-in-vivo
#8
Georg Karpel-Massler, Doruntina Ramani, Chang Shu, Marc-Eric Halatsch, Mike-Andrew Westhoff, Jeffrey N Bruce, Peter Canoll, Markus D Siegelin
Cancer cells display a variety of global metabolic changes, which aside from the glycolytic pathway largely involve amino acid metabolism. To ensure aggressive growth, tumor cells highly depend on amino acids, most notably due to their pivotal need of protein synthesis. In this study, we assessed the overall hypothesis that depletion of asparagine by E. coli-derived L-asparaginase might be a novel means for the therapy of one of the most recalcitrant neoplasms and for which no efficient treatment currently exists - glioblastoma (WHO grade IV)...
June 7, 2016: Oncotarget
https://www.readbyqxmd.com/read/27161692/po-03-khorana-score-and-histotype-predict-the-incidence-of-early-venous-thromboembolism-vte-in-non-hodgkin-lymphoma-nhl-a-pooled-data-analysis-of-twelve-clinical-trials-of-fondazione-italiana-linfomi-fil
#9
R M Santi, M Ceccarelli, G Catania, C Monagheddu, A Evangelista, E Bernocco, F Monaco, M Federico, U Vitolo, S Cortelazzo, M G Cabras, M Spina, L Baldini, C Boccomini, A Chiappella, A Bari, S Luminari, M Calabrese, A Levis, C Visco, L Contino, G Ciccone, M Ladetto
BACKGROUND: Recent studies show that the risk of VTE in NHL pts is similar to that observed in high risk solid tumors (i.e. pancreatic, ovarian cancer). VTE in NHL occurs in most cases within three months from diagnosis and can have substantial impact on treatment delivery and outcome as well as on quality of life. However few data are available on potential predictors. AIMS: To better clarify the epidemiology of early (within six months from treatment start) VTE in NHL we conducted a pooled data analysis of 12 clinical trials from FIL...
April 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27108554/-follicular-and-mantle-cell-lymphoma-diagnosed-in-biopsies-of-gastroenterocolic-region
#10
Lukáš Plank, Tomáš Balhárek, Peter Szépe
The authors present a retrospective analysis of follicular lymphomas (FL) and mantle cell lymphomas (MCL) diagnosed according to the WHO classification (2008) in consecutive biopsies of GI organs in a period of 11 years. The series includes 18 patients with FL verified in 22 biopsies and 44 patients with MCL diagnosed in 54 biopsies. FL represented always a solitary tumor, most often - up to ¾ of all the cases - of a small intestine, more often in its jejunoileal than duodenal parts. The biopsies were obtained almost equally by endoscopical approach, they were usually mucosal and rarely polypectomic, as well as by surgical resections (54,5 % and 45,5 % of the cases respectively)...
2016: Ceskoslovenská Patologie
https://www.readbyqxmd.com/read/26984211/results-of-a-phase-ii-study-of-vorinostat-in-combination-with-intravenous-fludarabine-mitoxantrone-and-dexamethasone-in-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-an-interim-analysis
#11
MULTICENTER STUDY
Dong-Yeop Shin, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Jee Hyun Kong, Jeong-A Kim, Byung-Su Kim, Hyo Jung Kim, Jong-Ho Won, Sung-Kyu Park, Won Seog Kim
PURPOSE: Mantle cell lymphoma (MCL) is a disease that frequently relapses and primarily affects elderly people. We performed an open-label, multi-center, phase II study to investigate the effect and quality of life (QoL) of treatment with vorinostat in combination with fludarabine, mitoxantrone and dexamethasone (V-FND) for relapsed or refractory MCL. METHODS: The treatment schedule was composed of four cycles of induction treatment with V-FND and subsequent consolidation therapy involving autologous hematopoietic stem cell transplantation or six cycles of vorinostat maintenance...
April 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/26899778/lenalidomide-versus-investigator-s-choice-in-relapsed-or-refractory-mantle-cell-lymphoma-mcl-002-sprint-a-phase-2-randomised-multicentre-trial
#12
RANDOMIZED CONTROLLED TRIAL
Marek Trněný, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, John Radford, Wojciech Jurczak, Franck Morschhauser, Julia Alexeeva, Simon Rule, Boris Afanasyev, Kamil Kaplanov, Antoine Thyss, Alexej Kuzmin, Sergey Voloshin, Kazimierz Kuliczkowski, Agnieszka Giza, Noel Milpied, Caterina Stelitano, Reinhard Marks, Lorenz Trümper, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Luca Arcaini
BACKGROUND: Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, showed activity in many single-group studies in relapsed or refractory mantle cell lymphoma. The aim of this randomised study was to examine the efficacy and safety of lenalidomide versus best investigator's choice of single-agent therapy in relapsed or refractory mantle cell lymphoma. METHODS: The MCL-002 (SPRINT) study was a randomised, phase 2 study of patients with mantle cell lymphoma aged 18 years or older at 67 clinics and academic centres in 12 countries who relapsed one to three times, had Eastern Cooperative Oncology Group performance status of 0-2, at least one measurable lesion to be eligible, and who were ineligible for intensive chemotherpy or stem-cell transplantation...
March 2016: Lancet Oncology
https://www.readbyqxmd.com/read/26857473/incidence-of-elbow-injuries-in-adolescent-baseball-players-screening-by-a-low-field-magnetic-resonance-imaging-system-specialized-for-small-joints
#13
Yoshikazu Okamoto, Kiyoshi Maehara, Tetsuya Kanahori, Takashi Hiyama, Takashi Kawamura, Manabu Minami
PURPOSE: The aim of this preliminary study was to examine the capability of screening for elbow injuries induced by baseball using a low field small joint MRI system. MATERIALS AND METHODS: Sixty-two players in the 4th-6th elementary school grades, with ages ranging from 9 to 12 years, participated in this study. Screening for elbow injuries was performed using a low-magnetic-field (0.2-T) magnetic resonance imaging (MRI) system designed for examinations of small joints of the extremities...
April 2016: Japanese Journal of Radiology
https://www.readbyqxmd.com/read/26542378/a-phase-1-clinical-trial-of-the-selective-btk-inhibitor-ono-gs-4059-in-relapsed-and-refractory-mature-b-cell-malignancies
#14
MULTICENTER STUDY
Harriet S Walter, Simon A Rule, Martin J S Dyer, Lionel Karlin, Ceri Jones, Bruno Cazin, Philippe Quittet, Nimish Shah, Claire V Hutchinson, Hideyuki Honda, Kevin Duffy, Joseph Birkett, Virginia Jamieson, Nigel Courtenay-Luck, Toshio Yoshizawa, John Sharpe, Tomoya Ohno, Shinichiro Abe, Akihisa Nishimura, Guillaume Cartron, Franck Morschhauser, Christopher Fegan, Gilles Salles
We report the results of a multicenter phase 1 dose-escalation study of the selective Bruton tyrosine kinase (BTK) inhibitor ONO/GS-4059 in 90 patients with relapsed/refractory B-cell malignancies. There were 9 dose-escalation cohorts ranging from 20 mg to 600 mg once daily with twice-daily regimens of 240 mg and 300 mg. Twenty-four of 25 evaluable chronic lymphocytic leukemia (CLL) patients (96%) responded to ONO/GS-4059, with a median treatment duration of 80 weeks; 21 CLL patients remain on treatment. Lymph node responses were rapid and associated with a concurrent lymphocytosis...
January 28, 2016: Blood
https://www.readbyqxmd.com/read/26511682/posterior-cruciate-ligament-reconstruction-via-tibial-inlay-technique-in-multiligament-knee-injuries
#15
Sinan Zehir, Nurzat Elmalı, Ercan Şahin, Murat Çalbıyık, Mustafa Karakaplan, Zeki Taşdemir
OBJECTIVE: The aim of this study is to report our institution's experience regarding the use of open tibial inlay technique in patients undergoing single-stage combined posterior cruciate ligament (PCL) reconstruction. METHODS: Records of 17 patients who underwent PCL reconstruction with tibial inlay technique were retrospectively reviewed. Patients with ipsilateral femoral or tibial osteochondral avulsion fractures or ipsilateral concomitant tibia and femur shaft fractures were excluded...
2015: Acta Orthopaedica et Traumatologica Turcica
https://www.readbyqxmd.com/read/26492567/phase-ii-trial-of-r-chop-plus-bortezomib-induction-therapy-followed-by-bortezomib-maintenance-for-newly-diagnosed-mantle-cell-lymphoma-swog-s0601
#16
MULTICENTER STUDY
Brian G Till, Hongli Li, Steven H Bernstein, Richard I Fisher, W Richard Burack, Lisa M Rimsza, Justin D Floyd, Marco A DaSilva, Dennis F Moore, Olga Pozdnyakova, Sonali M Smith, Michael LeBlanc, Jonathan W Friedberg
Bortezomib is active in mantle cell lymphoma (MCL), with approval in upfront and relapsed settings. Given inevitable recurrence following induction chemoimmunotherapy, maintenance approaches are a rational strategy to improve clinical outcomes. We conducted a phase II study to evaluate the safety and efficacy of six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) plus bortezomib (1.3 mg/m2 days 1 and 4 of 21 d cycles) followed by bortezomib maintenance (1.3 mg/m2 days 1, 4, 8, and 11 every 3 months for 2 years)...
January 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26165355/developmental-competence-of-different-quality-bovine-oocytes-retrieved-through-ovum-pick-up-following-in-vitro-maturation-and-fertilization
#17
N Saini, M K Singh, S M Shah, K P Singh, R Kaushik, R S Manik, S K Singla, P Palta, M S Chauhan
In the present study, oocytes retrieved from cross bred Karan Fries cows by ovum pick-up technique were graded into Group 1 and Group 2, based on the morphological appearance of the individual cumulus-oocyte complexes (COCs). To analyze whether the developmental potential of the COCs bears a relation to morphological appearance, relative expression of a panel of genes associated with; (a) cumulus-oocyte interaction (Cx43, Cx37, GDF9 and BMP15), (b) fertilization (ZP2 and ZP3), (c) embryonic development (HSF1, ZAR1 and bFGF) and (d) apoptosis and survival (BAX, BID and BCL-XL, MCL-1, respectively) was studied at two stages: germinal vesicle (GV) stage and after in vitro maturation...
December 2015: Animal: An International Journal of Animal Bioscience
https://www.readbyqxmd.com/read/26149653/role-of-gelsolin-in-cell-proliferation-and-invasion-of-human-hepatocellular-carcinoma-cells
#18
Biao Deng, JiaQing Fang, XiaoFei Zhang, Lei Qu, ZhongWei Cao, Bin Wang
Gelsolin (GSN), one of the most important actin structure regulating proteins, has been implicated in the oncogenesis of some cancers. In this study, we investigated the expression of GSN in hepatocellular carcinoma (HCC) and revealed its potential mechanisms. The mRNA and protein levels of GSN were overexpressed in HCC cells and HCC tissues compared to adjacent noncancerous tissues. GSN expression was correlated with venous invasion (P=0.0199) and Edmonson grading (P=0.0344) expression in HCC. Overexpression of GSN in Huh7 and SMMC-7721 cells significantly promoted cell proliferation and the number of Matrigel™-invading cells compared with control cells, with increased expression of matrix metalloproteinase MCL-1, MMP-2 and MMP-9, a key regulator of growth and invasion...
October 25, 2015: Gene
https://www.readbyqxmd.com/read/26122866/bendamustine-as-first-line-treatment-in-patients-with-advanced-indolent-non-hodgkin-lymphoma-and-mantle-cell-lymphoma-in-german-routine-clinical-practice
#19
M Becker, B Tschechne, M Reeb, U Schwinger, H-R Bruch, M Frank, L Straßl
Bendamustine has demonstrated clinical activity and a favorable safety profile as monotherapy or in combination with rituximab in lymphoid malignancies. As interventional trials do not always reflect clinical reality, we were interested in the treatment modalities and the outcome of bendamustine-based first-line therapy in patients with advanced indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) in routine practice. Between April 2010 and October 2011, 324 patients were enrolled in a prospective non-interventional multicenter study...
September 2015: Annals of Hematology
https://www.readbyqxmd.com/read/26059948/long-term-follow-up-of-mcl-patients-treated-with-single-agent-ibrutinib-updated-safety-and-efficacy-results
#20
MULTICENTER STUDY
Michael L Wang, Kristie A Blum, Peter Martin, Andre Goy, Rebecca Auer, Brad S Kahl, Wojciech Jurczak, Ranjana H Advani, Jorge E Romaguera, Michael E Williams, Jacqueline C Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, Peter Johnson, Stephen E Spurgeon, Liang Zhang, Linda Baher, Mei Cheng, Dana Lee, Darrin M Beaupre, Simon Rule
Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy. We report the updated safety and efficacy results from the multicenter, open-label phase 2 registration trial of ibrutinib (median 26.7-month follow-up). Patients (N = 111) received oral ibrutinib 560 mg once daily, and those with stable disease or better could enter a long-term extension study. The primary end point was overall response rate (ORR). The median patient age was 68 years (range, 40-84), with a median of 3 prior therapies (range, 1-5)...
August 6, 2015: Blood
keyword
keyword
31645
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"